Treatment News : CD4s at Entry Into HIV Care Largely Unchanged in 20 Years

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » August 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


August 21, 2013

CD4s at Entry Into HIV Care Largely Unchanged in 20 Years

For people with HIV living in resource-rich nations, the average CD4 count upon entry into care has not seen an appreciable increase during the past two decades, aidsmap reports. As of 2011, that figure was 336. The finding has major implications for the current debate over the best timing for beginning antiretrovirals, implying that policies to start therapy at 500 CD4s rather than 350 lose their poignancy when so many HIV-positive people present themselves to care relatively late in the course of their infection.

Publishing their findings in Clinical Infectious Diseases, researchers from the United States and the United Kingdom conducted a systematic review of 44 studies, including data spanning from 1992 to 2011, on the CD4 counts when entering care of 169,000 people with HIV. The studies were largely from the United States and United Kingdom with a respective 18 and 11 between them.

In 1992, the average CD4 count upon entry into care was 307. By 2011, this figure rose to 336, for an increase of 1.5 cells each year. However, statistically, the CD4 level remained essentially unchanged, meaning any apparent differences could have been explained by chance. Furthermore, the proportion of those entering care late or very late reduced only slightly during the two-decade period, with a reduction of just 0.1 percent per year.

The authors wrote, “Our study findings indicate that the considerations of when to start [therapy] may be immaterial for the majority of patients who continue to enter care below any of the recommended treatment thresholds.”

In an accompanying editorial, Joep Lange, MD, a professor of medicine and head of the Department of Global Health at the Academic Medical Center at the University of Amsterdam in the Netherlands, wrote, “The finding that so little has changed with regard to time of presentation to HIV care in a period that saw dramatic improvements in HIV treatment and monitoring is astonishing.”

To read the aidsmap story, click here.

To read the study abstract, click here.

To read an editorial commentary about the study, published in CID, click here.

Search: CD4, entry into care, aidsmap, Clinical Infectious Diseases, 350, 500, HIV, Joep Lange.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

  comments 1 - 1 (of 1 total)    

VJS, Austin, 2013-08-28 14:12:41
I started on Atripla in Jan 2004. Cd4 cnt. was 280, now last check up was 1615 in Jan 2013.

comments 1 - 1 (of 1 total)    

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.